p.117 抽出テキスト
888. Protonotarios A, Wicks E, Ashworth M, Stephenson E, Guttmann O, Savvatis K, et al. Prevalence of (18)F-fluorodeoxyglucose positron emission tomography abnormalities in patients with arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol 2019; 284:99–104. https://doi.org/10.1016/j.ijcard.2018.10.083 889. Casella M, Gasperetti A, Sicuso R, Conte E, Catto V, Sommariva E, et al. Characteristics of patients with arrhythmogenic left ventricular cardiomyopathy: combining genetic and histopathologic findings. Circ Arrhythm Electrophysiol 2020;13:e009005. https:// doi.org/10.1161/CIRCEP.120.009005 890. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 1988;318:129–133. https://doi.org/10. 1056/NEJM198801213180301 891. Protonotarios A, Anastasakis A, Panagiotakos DB, Antoniades L, Syrris P, Vouliotis A, et al. Arrhythmic risk assessment in genotyped families with arrhythmogenic right ventricular cardiomyopathy. Europace 2016;18:610–616. https://doi.org/10.1093/ europace/euv061 892. Corrado D, van Tintelen PJ, McKenna WJ, Hauer RNW, Anastastakis A, Asimaki A, et al. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. Eur Heart J 2020;41:1414–1429. https://doi. org/10.1093/eurheartj/ehz669 893. Cipriani A, Bauce B, De Lazzari M, Rigato I, Bariani R, Meneghin S, et al. Arrhythmogenic right ventricular cardiomyopathy: characterization of left ventricular phenotype and differential diagnosis with dilated cardiomyopathy. J Am Heart Assoc 2020;9:e014628. https://doi.org/10.1161/JAHA.119.014628 894. Sen-Chowdhry S, Syrris P, Prasad SK, Hughes SE, Merrifield R, Ward D, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol 2008;52:2175–2187. https://doi.org/10.1016/j.jacc.2008.09.019 895. Bhonsale A, Groeneweg JA, James CA, Dooijes D, Tichnell C, Jongbloed JD, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/ cardiomyopathy-associated mutation carriers. Eur Heart J 2015;36:847–855. https:// doi.org/10.1093/eurheartj/ehu509 896. Hermida A, Fressart V, Hidden-Lucet F, Donal E, Probst V, Deharo JC, et al. High risk of heart failure associated with desmoglein-2 mutations compared to plakophilin-2 mutations in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Heart Fail 2019;21:792–800. https://doi.org/10.1002/ejhf.1423 897. DeWitt ES, Chandler SF, Hylind RJ, Beausejour Ladouceur V, Blume ED, VanderPluym C, et al. Phenotypic manifestations of arrhythmogenic cardiomyopathy in children and adolescents. J Am Coll Cardiol 2019;74:346–358. https://doi.org/10.1016/j.jacc.2019.05. 022 898. Protonotarios A, Elliott PM. Arrhythmogenic right ventricular cardiomyopathy as a hidden cause of paediatric myocarditis presentation. Int J Cardiol 2018;271:113–114. https://doi.org/10.1016/j.ijcard.2018.06.117 899. Bosman LP, Cadrin-Tourigny J, Bourfiss M, Aliyari Ghasabeh M, Sharma A, Tichnell C, et al. Diagnosing arrhythmogenic right ventricular cardiomyopathy by 2010 Task Force Criteria: clinical performance and simplified practical implementation. Europace 2020; 22:787–796. https://doi.org/10.1093/europace/euaa039 900. Platonov PG, Calkins H, Hauer RN, Corrado D, Svendsen JH, Wichter T, et al. High interobserver variability in the assessment of epsilon waves: implications for diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm 2016;13: 208–216. https://doi.org/10.1016/j.hrthm.2015.08.031 901. Protonotarios A, Anastasakis A, Tsatsopoulou A, Antoniades L, Prappa E, Syrris P, et al. Clinical significance of epsilon waves in arrhythmogenic cardiomyopathy. J Cardiovasc Electrophysiol 2015;26:1204–1210. https://doi.org/10.1111/jce.12755 902. Gasperetti A, Cappelletto C, Carrick R, Targetti M, Tichnell C, Martino A, et al. Association of premature ventricular contraction burden on serial Holter monitoring with arrhythmic risk in patients with arrhythmogenic right ventricular cardiomyopathy. JAMA Cardiol 2022;7:378–385. https://doi.org/10.1001/jamacardio.2021.6016 903. Corrado D, Basso C, Leoni L, Tokajuk B, Bauce B, Frigo G, et al. Three-dimensional electroanatomic voltage mapping increases accuracy of diagnosing arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2005;111:3042–3050. https:// doi.org/10.1161/CIRCULATIONAHA.104.486977 904. Hoogendoorn JC, Sramko M, Venlet J, Siontis KC, Kumar S, Singh R, et al. Electroanatomical voltage mapping to distinguish right-sided cardiac sarcoidosis from arrhythmogenic right ventricular cardiomyopathy. JACC Clin Electrophysiol 2020;6:696–707. https://doi.org/10.1016/j.jacep.2020.02.008 905. Avella A, d’Amati G, Pappalardo A, Re F, Silenzi PF, Laurenzi F, et al. Diagnostic value of endomyocardial biopsy guided by electroanatomic voltage mapping in arrhythmogenic right ventricular cardiomyopathy/dysplasia. J Cardiovasc Electrophysiol 2008;19: 1127–1134. https://doi.org/10.1111/j.1540-8167.2008.01228.x 906. Casella M, Dello Russo A, Bergonti M, Catto V, Conte E, Sommariva E, et al. Diagnostic yield of electroanatomic voltage mapping in guiding endomyocardial biopsies. Circulation 2020;142:1249–1260. https://doi.org/10.1161/CIRCULATIONAHA.120. 046900 907. Tessier R, Marteau L, Vivien M, Guyomarch B, Thollet A, Fellah I, et al. 18F-Fluorodeoxyglucose positron emission tomography for the detection of myocardial inflammation in arrhythmogenic left ventricular cardiomyopathy. Circ Cardiovasc Imaging 2022;15:e014065. https://doi.org/10.1161/CIRCIMAGING.122.014065 908. Gasperetti A, Rossi VA, Chiodini A, Casella M, Costa S, Akdis D, et al. Differentiating hereditary arrhythmogenic right ventricular cardiomyopathy from cardiac sarcoidosis fulfilling 2010 ARVC Task Force Criteria. Heart Rhythm 2021;18:231–238. https://doi. org/10.1016/j.hrthm.2020.09.015 909. Laredo M, Duthoit G, Gandjbakhch E, Redheuil A, Hebert J-L. Total pericardium agenesis mistaken for arrhythmogenic right ventricular cardiomyopathy. Eur Heart J Cardiovasc Imaging 2018;19:120. https://doi.org/10.1093/ehjci/jex251 910. Castelletti S, Crotti L, Dagradi F, Rella V, Salerno S, Parati G, et al. Partial pericardial agenesis mimicking arrhythmogenic right ventricular cardiomyopathy. Clin J Sport Med 2020;30:e159–e162. https://doi.org/10.1097/JSM.0000000000000733 911. Brosnan MJ, Te Riele A, Bosman LP, Hoorntje ET, van den Berg MP, Hauer RNW, et al. Electrocardiographic features differentiating arrhythmogenic right ventricular cardiomyopathy from an athlete’s heart. JACC Clin Electrophysiol 2018;4:1613–1625. https://doi.org/10.1016/j.jacep.2018.09.008 912. D’Ascenzi F, Solari M, Corrado D, Zorzi A, Mondillo S. Diagnostic differentiation between arrhythmogenic cardiomyopathy and athlete’s heart by using imaging. JACC Cardiovasc Imaging 2018;11:1327–1339. https://doi.org/10.1016/j.jcmg.2018.04.031 913. Rossi VA, Niederseer D, Sokolska JM, Kovacs B, Costa S, Gasperetti A, et al. A novel diagnostic score integrating atrial dimensions to differentiate between the athlete’s heart and arrhythmogenic right ventricular cardiomyopathy. J Clin Med 2021;10: 4094. https://doi.org/10.3390/jcm10184094 914. van Tintelen JP, Van Gelder IC, Asimaki A, Suurmeijer AJH, Wiesfeld ACP, Jongbloed JDH, et al. Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. Heart Rhythm 2009;6: 1574–1583. https://doi.org/10.1016/j.hrthm.2009.07.041 915. Merner ND, Hodgkinson KA, Haywood AFM, Connors S, French VM, Drenckhahn JD, et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet 2008;82:809–821. https://doi.org/10.1016/j.ajhg.2008.01.010 916. Costa S, Medeiros-Domingo A, Gasperetti A, Akdis D, Berger W, James CA, et al. Impact of genetic variant reassessment on the diagnosis of arrhythmogenic right ventricular cardiomyopathy based on the 2010 Task Force Criteria. Circ Genom Precis Med 2021;14:e003047. https://doi.org/10.1161/CIRCGEN.120.003047 917. Elliott PM, Anastasakis A, Asimaki A, Basso C, Bauce B, Brooke MA, et al. Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. Eur J Heart Fail 2019;21:955–964. https://doi.org/10.1002/ejhf.1534 918. Gasperetti A, Targetti M, Olivotto I. Anti-arrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: the importance of optimal beta-blocker dose titration. Int J Cardiol 2021;338:150–151. https://doi.org/10.1016/j.ijcard.2021.06.009 919. Corrado D, Wichter T, Link MS, Hauer R, Marchlinski F, Anastasakis A, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Eur Heart J 2015;36:3227–3237. https://doi. org/10.1093/eurheartj/ehv162 920. Cappelletto C, Gregorio C, Barbati G, Romani S, De Luca A, Merlo M, et al. Antiarrhythmic therapy and risk of cumulative ventricular arrhythmias in arrhythmogenic right ventricle cardiomyopathy. Int J Cardiol 2021;334:58–64. https://doi.org/ 10.1016/j.ijcard.2021.04.069 921. Marcus GM, Glidden DV, Polonsky B, Zareba W, Smith LM, Cannom DS, et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol 2009;54:609–615. https:// doi.org/10.1016/j.jacc.2009.04.052 922. Wichter T, Borggrefe M, Haverkamp W, Chen X, Breithardt G. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 1992;86:29–37. https://doi.org/10.1161/01.CIR.86.1.29 923. Ermakov S, Gerstenfeld EP, Svetlichnaya Y, Scheinman MM. Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2017;14:564–569. https://doi.org/10.1016/j.hrthm.2016. 12.010 924. Rolland T, Badenco N, Maupain C, Duthoit G, Waintraub X, Laredo M, et al. Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. Europace 2022;24:278–284. https://doi.org/10.1093/europace/ euab182 925. Daimee UA, Assis FR, Murray B, Tichnell C, James CA, Calkins H, et al. Clinical outcomes of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy: insights from the Johns Hopkins ARVC Program. Heart Rhythm 2021;18:1369–1376. https://doi.org/10.1016/j.hrthm.2021.04.028 926. Mathew S, Saguner AM, Schenker N, Kaiser L, Zhang P, Yashuiro Y, et al. Catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia: a sequential approach. J Am Heart Assoc 2019;8:e010365. https://doi.org/10.1161/JAHA.118.010365 927. Gandjbakhch E, Laredo M, Berruezo A, Gourraud JB, Sellal JM, Martins R, et al. Outcomes after catheter ablation of ventricular tachycardia without implantable cardioverter-defibrillator in selected patients with arrhythmogenic right ventricular cardiomyopathy. Europace 2021;23:1428–1436. https://doi.org/10.1093/europace/ euab172 ESC Guidelines 3619 Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026